The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.

MLA

Eslami, Gholamali, et al. “The Impact of Sofosbuvir/Daclatasvir or Ribavirin in Patients with Severe COVID-19.” The Journal of Antimicrobial Chemotherapy, vol. 75, no. 11, Nov. 2020, pp. 3366–72. EBSCOhost, https://doi.org/10.1093/jac/dkaa331.

APA

Eslami, G., Mousaviasl, S., Radmanesh, E., Jelvay, S., Bitaraf, S., Simmons, B., Wentzel, H., Hill, A., Sadeghi, A., Freeman, J., Salmanzadeh, S., Esmaeilian, H., Mobarak, M., Tabibi, R., Jafari Kashi, A. H., Lotfi, Z., Talebzadeh, S. M., Wickramatillake, A., Momtazan, M., … Mobarak, S. (2020). The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. The Journal of Antimicrobial Chemotherapy, 75(11), 3366–3372. https://doi.org/10.1093/jac/dkaa331

Chicago

Eslami, Gholamali, Sajedeh Mousaviasl, Esmat Radmanesh, Saeed Jelvay, Saeid Bitaraf, Bryony Simmons, Hannah Wentzel, et al. 2020. “The Impact of Sofosbuvir/Daclatasvir or Ribavirin in Patients with Severe COVID-19.” The Journal of Antimicrobial Chemotherapy 75 (11): 3366–72. doi:10.1093/jac/dkaa331.